228 related articles for article (PubMed ID: 25894594)
1. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
Melguizo-Gavilanes I; Bruner JM; Guha-Thakurta N; Hess KR; Puduvalli VK
J Neurooncol; 2015 May; 123(1):141-50. PubMed ID: 25894594
[TBL] [Abstract][Full Text] [Related]
2. Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis.
Gunjur A; Lau E; Taouk Y; Ryan G
J Med Imaging Radiat Oncol; 2011 Dec; 55(6):603-10. PubMed ID: 22141608
[TBL] [Abstract][Full Text] [Related]
3. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
4. Pseudoprogression in glioblastoma patients: the impact of extent of resection.
Park HH; Roh TH; Kang SG; Kim EH; Hong CK; Kim SH; Ahn SS; Lee SK; Choi HJ; Cho J; Kim SH; Lee KS; Suh CO; Chang JH
J Neurooncol; 2016 Feb; 126(3):559-66. PubMed ID: 26608521
[TBL] [Abstract][Full Text] [Related]
5. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
6. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topkan E; Topuk S; Oymak E; Parlak C; Pehlivan B
Am J Clin Oncol; 2012 Jun; 35(3):284-9. PubMed ID: 21399487
[TBL] [Abstract][Full Text] [Related]
7. Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogression from true tumor progression.
Hansen MR; Pan E; Wilson A; McCreary M; Wang Y; Stanley T; Pinho MC; Guo X; Okuda DT
J Neurooncol; 2018 Sep; 139(3):731-738. PubMed ID: 29882044
[TBL] [Abstract][Full Text] [Related]
8. MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
Kim BR; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
PLoS One; 2016; 11(11):e0166096. PubMed ID: 27835666
[TBL] [Abstract][Full Text] [Related]
9. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
[TBL] [Abstract][Full Text] [Related]
10. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.
Wang S; Martinez-Lage M; Sakai Y; Chawla S; Kim SG; Alonso-Basanta M; Lustig RA; Brem S; Mohan S; Wolf RL; Desai A; Poptani H
AJNR Am J Neuroradiol; 2016 Jan; 37(1):28-36. PubMed ID: 26450533
[TBL] [Abstract][Full Text] [Related]
11. MRI findings and pathological features in early-stage glioblastoma.
Ideguchi M; Kajiwara K; Goto H; Sugimoto K; Nomura S; Ikeda E; Suzuki M
J Neurooncol; 2015 Jun; 123(2):289-97. PubMed ID: 25939441
[TBL] [Abstract][Full Text] [Related]
12. Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Kang HC; Kim CY; Han JH; Choe GY; Kim JH; Kim JH; Kim IA
J Neurooncol; 2011 Mar; 102(1):157-62. PubMed ID: 20632071
[TBL] [Abstract][Full Text] [Related]
13. The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Bulik M; Kazda T; Slampa P; Jancalek R
Biomed Res Int; 2015; 2015():641023. PubMed ID: 26448943
[TBL] [Abstract][Full Text] [Related]
14. Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
van West SE; de Bruin HG; van de Langerijt B; Swaak-Kragten AT; van den Bent MJ; Taal W
Neuro Oncol; 2017 May; 19(5):719-725. PubMed ID: 28453748
[TBL] [Abstract][Full Text] [Related]
15. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
16. Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma.
Abdulla S; Saada J; Johnson G; Jefferies S; Ajithkumar T
Clin Radiol; 2015 Nov; 70(11):1299-312. PubMed ID: 26272530
[TBL] [Abstract][Full Text] [Related]
17. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
[TBL] [Abstract][Full Text] [Related]
19. Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients.
Kerkhof M; Tans PL; Hagenbeek RE; Lycklama À Nijeholt GJ; Holla FK; Postma TJ; Straathof CS; Dirven L; Taphoorn MJ; Vos MJ
CNS Oncol; 2017 Oct; 6(4):297-306. PubMed ID: 28984142
[TBL] [Abstract][Full Text] [Related]
20. Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
Fabi A; Russillo M; Metro G; Vidiri A; Di Giovanni S; Cognetti F
Anticancer Res; 2009 Jul; 29(7):2607-10. PubMed ID: 19596935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
